Clover Health Investments, Corp. The company is headquartered in Franklin, Tennessee.
| Revenue (TTM) | $2.48B |
| Gross Profit (TTM) | $459.13M |
| EBITDA | $-17.96M |
| Operating Margin | 3.77% |
| Return on Equity | -5.10% |
| Return on Assets | -1.77% |
| Revenue/Share (TTM) | $4.77 |
| Book Value | $0.71 |
| Price-to-Book | 6.45 |
| Price-to-Sales (TTM) | 0.96 |
| EV/Revenue | 0.847 |
| EV/EBITDA | -0.65 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 55.60% |
| Shares Outstanding | $435.44M |
| Float | $413.26M |
| % Insiders | 4.25% |
| % Institutions | 34.00% |
Volatility is currently expanding
WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J.
Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention and the maturation of member cohorts, Interim Chief Financial Officer Clay Thornton said at Jefferies' Healthcare Services and Technology Conference in Nashville.
WILMINGTON, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following investor conferences: Interim Chief Financial Officer, Clay Thornton, will present at the 2026 Jefferies Healthcare Services and Technology Conference on Tuesday, September 15, 2026, at 1:40 p.m.
Clover Health Investments, Corp. leverages its AI-powered Clover Assistant to drive lower claims costs and improve member profitability. Baseline and bullish DCF valuations yield fair values of $5.02 and $14.10 per share, respectively, versus the current $4.15 price. Key upside drivers include rapid membership growth, AI-enabled cost savings, and a potential $120M Medicare Advantage bonus tied to a 4.5-star CMS rating.
Clover Health (CLOV) has delivered strong growth, profitability, and improved guidance, supporting my continued Strong Buy rating. CLOV's Medicare Advantage membership grew 48% YoY, with revenue up 56% and gross profit up 54%, driven by cohort maturation and the Clover Assistant platform. Valuation remains attractive at a 78% discount to sector median EV/sales, with upside potential if per-member profitability and SaaS revenue trends persist.
Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage model around earlier identification and treatment of chronic conditions, Interim Chief Financial Officer Clay Thornton said during a Canaccord Genuity conference presentation.
Business Highlights: Delivered strong second quarter 2026 GAAP Net Income alongside continued market-leading Medicare Advantage membership growth Improved Full Year 2026 guidance across all metrics Increasing confidence for 2027 outlook, supported by strong cohort development, continued clinical engagement, and the added flexibility of a 4.5 Star payment year Financial Results: Second quarter 2026 GAAP Net Income of $28 million, an improvement of $39 million year-over-year Second quarter 2026 Medicare Advantage membership of 157,309, up 48% year-over-year, and Total revenues of $743 million, up 56% year-over-year Second quarter 2026 Consolidated Gross Profit of $153 million, up 54% year-over-year, and Adjusted EBITDA of $41 million, up 139% year-over-year Improved Full Year 2026 Guidance: Average Medicare Advantage membership of 156,000 - 158,000, representing 47% growth year-over-year at the midpoint Total revenues between $2.92 billion and $3.00 billion, representing 54% growth year-over-year at the midpoint Consolidated Gross Profit between $525 million and $555 million, representing 52% growth year-over-year at the midpoint Adjusted EBITDA profitability between $70 million and $85 million GAAP Net Income between $20 million and $35 million WILMINGTON, Del., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the second quarter 2026.
Clover Health (NASDAQ:CLOV) has spent years as a speculative bet on a technology-led Medicare Advantage model.
WILMINGTON, Del., July 22, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Interim Chief Financial Officer, Clay Thornton, will present at the 2026 Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 8:30 a.m.
Clover Health Investments said in a regulatory filing on Friday that it detected unusual login activity on some of its information systems on July 4 and later found a hacker had gained access to three employee accounts through social engineering.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CLOV and any ticker you trade — then tracks every position and per-strategy win rate.
